Angiotensin receptor blockers and myocardial infarction.
作者信息
Verma Subodh, Strauss Marty
出版信息
BMJ. 2004 Nov 27;329(7477):1248-9. doi: 10.1136/bmj.329.7477.1248.
Abstract
摘要
相似文献
1
Angiotensin receptor blockers and myocardial infarction.血管紧张素受体阻滞剂与心肌梗死
BMJ. 2004 Nov 27;329(7477):1248-9. doi: 10.1136/bmj.329.7477.1248.
2
Two amlodipine/ARB combinations for hypertension.两种氨氯地平/血管紧张素受体阻滞剂联合用药治疗高血压
Med Lett Drugs Ther. 2007 Dec 17;49(1276):101-2.
3
Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
J Hypertens. 2006 Aug;24(8):1679-81; author reply 1681-2. doi: 10.1097/01.hjh.0000239307.86248.80.
4
Exforge HCT.氨氯地平阿托伐他汀钙片
Med Lett Drugs Ther. 2009 Jun 15;51(1314):47.
5
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].[预防高血压的靶器官损害。VALUE研究对全科医疗有何意义？]
MMW Fortschr Med. 2004 Jul 8;146(27-28):41.
6
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
MMW Fortschr Med. 2006 May 4;148(18):42-3.
7
Aliskiren/valsartan (Valturna) for hypertension.阿利吉仑/缬沙坦（代文缬沙坦胶囊）用于治疗高血压。
Med Lett Drugs Ther. 2009 Nov 30;51(1326):94-5.
8
9
The X-cellent Study.卓越研究。
Am J Hypertens. 2006 Jan;19(1):8-9. doi: 10.1016/j.amjhyper.2005.07.003.
10
Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.氨氯地平/缬沙坦单片复方制剂：在高血压治疗中的应用评价。
Am J Cardiovasc Drugs. 2009;9(5):309-30. doi: 10.2165/11201120-000000000-00000.
引用本文的文献
1
Exploring the Cardiovascular Protective Effects of Baicalin: A Pathway to New Therapeutic Insights.探索黄芩苷的心血管保护作用：通往新治疗见解的途径。
Curr Top Med Chem. 2025;25(2):163-171. doi: 10.2174/0115680266347503241008075106.
2
Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.慢性阻塞性肺疾病与动脉粥样硬化：共同的发病机制与治疗新策略。
Clin Sci (Lond). 2022 Mar 31;136(6):405-423. doi: 10.1042/CS20210835.
3
Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents.新型药物洗脱支架成功植入后急性心肌梗死后合并糖尿病前期患者中血管紧张素转换酶抑制剂与血管紧张素 II 型 1 受体阻滞剂的比较
Cardiol J. 2023;30(4):614-626. doi: 10.5603/CJ.a2021.0116. Epub 2021 Oct 8.
4
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂可能与肺腺癌风险相关：一项基于全国人群的巢式病例对照研究。
Am J Transl Res. 2020 Oct 15;12(10):6615-6625. eCollection 2020.
5
Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂对既往心肌梗死患者的疗效比较
Open Heart. 2019 May 4;6(1):e001010. doi: 10.1136/openhrt-2019-001010. eCollection 2019.
6
Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents.在接受药物洗脱支架PCI的非ST段抬高型心肌梗死患者中，β受体阻滞剂联合ACEI或ARB的长期临床结局。
J Geriatr Cardiol. 2019 Mar;16(3):280-290. doi: 10.11909/j.issn.1671-5411.2019.03.010.
7
Effects of Ivabradine on Left Ventricular Systolic Function and Cardiac Fibrosis in Rat Myocardial Ischemia-Reperfusion Model.伊伐布雷定对大鼠心肌缺血-再灌注模型左心室收缩功能及心肌纤维化的影响
Chonnam Med J. 2018 Sep;54(3):167-172. doi: 10.4068/cmj.2018.54.3.167. Epub 2018 Sep 27.
8
Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium.胸腺素β4可促进梗死心肌中移植的内皮祖细胞的存活和血管生成。
Int J Mol Med. 2017 Jun;39(6):1347-1356. doi: 10.3892/ijmm.2017.2950. Epub 2017 Apr 11.
9
Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.雷米普利与替米沙坦对高血压患者内皮功能改善作用的反应性充血指数比较
Clin Hypertens. 2017 Feb 15;23:4. doi: 10.1186/s40885-016-0060-y. eCollection 2017.
10
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.成人糖尿病患者肾素-血管紧张素系统阻断的心血管和肾脏结局：一项网状Meta分析的系统评价
PLoS Med. 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. eCollection 2016 Mar.
本文引用的文献
1
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂对糖尿病肾病患者死亡率和肾脏结局的影响：系统评价
BMJ. 2004 Oct 9;329(7470):828. doi: 10.1136/bmj.38237.585000.7C. Epub 2004 Sep 30.
2
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.两项大型、简单、随机试验的原理、设计及基线特征，这两项试验评估替米沙坦、雷米普利及其联合用药在高危患者中的疗效：替米沙坦单药及与雷米普利联合应用的全球终点试验/替米沙坦在不耐受血管紧张素转换酶抑制剂的心血管疾病患者中的随机评估研究（ONTARGET/TRANSCEND）试验
Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020.
3
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.缬沙坦或氨氯地平治疗方案用于治疗心血管高危高血压患者的疗效：VALUE随机试验
Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.
4
Is GSK guilty of fraud?葛兰素史克（GSK）是否犯有欺诈罪？
Lancet. 2004 Jun 12;363(9425):1919. doi: 10.1016/S0140-6736(04)16435-0.
5
Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.血管紧张素II 2型受体在心血管疾病中会产生有害作用吗？对肾素-血管紧张素系统治疗性阻断的启示。
Circulation. 2004 Jan 6;109(1):8-13. doi: 10.1161/01.CIR.0000096609.73772.C5.
6
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.坎地沙坦对慢性心力衰竭且左心室射血分数保留患者的影响：CHARM-保留试验
Lancet. 2003 Sep 6;362(9386):777-81. doi: 10.1016/S0140-6736(03)14285-7.
7
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.坎地沙坦对不能耐受血管紧张素转换酶抑制剂的慢性心力衰竭且左心室收缩功能降低患者的影响：CHARM替代试验
Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5.
8
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.老年人认知与预后研究（SCOPE）：一项随机双盲干预试验的主要结果
J Hypertens. 2003 May;21(5):875-86. doi: 10.1097/00004872-200305000-00011.
9
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.氯沙坦干预降低高血压终点事件研究（LIFE）中的心血管发病率和死亡率：一项与阿替洛尔对比的随机试验。
Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3.
10
Blood-pressure reduction and cardiovascular risk in HOPE study.HOPE研究中的血压降低与心血管风险
Lancet. 2001;358(9299):2130-1. doi: 10.1016/S0140-6736(01)07186-0.
Zotero 插件